Iván Bottoli
YOU?
Author Swipe
Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial Open
Rationale: CFTR (cystic fibrosis transmembrane conductance regulator) dysfunction is associated with mucus accumulation and worsening chronic obstructive pulmonary disease (COPD) symptoms. Objectives: The aim of this phase IIb dose-finding…
Ligelizumab impairs <span>IgE</span>‐binding to plasmacytoid dendritic cells more potently than omalizumab and restores <span>IFN</span>‐α production and <span>FOXP3</span><sup>+</sup> Treg generation Open
Background Ligelizumab is an anti‐IgE monoclonal antibody binding IgE with higher affinity than omalizumab that is under clinical investigation for several IgE‐mediated diseases. We previously showed that omalizumab removes IgE bound to Fc…
The rationale for development of ligelizumab in food allergy Open
Food allergy (FA) is a growing healthcare problem worldwide and the rising prevalence in many countries can be attributed to lifestyle, environmental, and nutritional changes. Immunoglobulin E (IgE)-mediated FA is the most common form of F…
Ligelizumab treatment for severe asthma: learnings from the clinical development programme Open
Objective Ligelizumab is a humanised IgG1 anti‐IgE antibody that binds IgE with higher affinity than omalizumab. Ligelizumab had greater efficacy than omalizumab on inhaled and skin allergen provocation responses in mild allergic asthma. T…